MedTrace Logo

A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma

NCT01983410 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2025-12-30

No results posted yet for this study

Summary

The purpose of this study is to better understand why pancreatic cancer develops in some people who are known carriers of the gene mutation (an abnormality) called BRCA, or its close relative PALB2. The investigators hope to do this by establishing a BRCA/PALB2 mutation carriers Pancreatic Ductal Adenocarcinoma (the common form of pancreatic cancer) Registry. A registry is a database of information.

Conditions

Interventions

BEHAVIORAL

The risk assessment questionnaire

OTHER

Blood specimens

OTHER

tumor tissue samples will be requested

Sponsors & Collaborators

Principal Investigators

  • David Kelsen, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-04
Primary Completion
2026-11-30
Completion
2026-11-30

Countries

  • United States
  • Israel

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01983410 on ClinicalTrials.gov